China Liver Cancer Clinical Registry Cohort Database (HEAL)
Anhui Provincial Hospital
10,000 participants
Jan 1, 2025
OBSERVATIONAL
Conditions
Summary
This study was led by the Department of Hepatobiliary Surgery of the First Affiliated Hospital of the University of Science and Technology of China (USTC), in close cooperation with many participating units across the country, to establish a standardized clinical information database of hepatocellular carcinoma cohorts, which will provide a guarantee for conducting high-quality real-world clinical studies and clinical research.
Eligibility
Inclusion Criteria3
- Age ≥ 18 years, no gender limit
- Patients without surgery are initially diagnosed with hepatocellular carcinoma, intrahepatic cholangiocarcinoma, mixed hepatocellular carcinoma-cholangiocarcinoma, or metastatic hepatocellular carcinoma based on the results of imaging and laboratory tests, or patients with surgery are diagnosed with hepatocellular carcinoma, intrahepatic cholangiocarcinoma, mixed hepatocellular carcinoma-cholangiocarcinoma, or metastatic hepatocellular carcinoma based on the results of pathologic tests
- Signed informed consent, good compliance, willingness to accept follow-up and provide blood and postoperative pathology residual samples
Exclusion Criteria4
- Combination of severe central nervous system disease, respiratory disease, autoimmune disease, chronic renal insufficiency, long-term use of immunosuppressive drugs, combination of severe uncontrolled infections
- Concurrent active cardiovascular disease, cerebrovascular accident within 6 months, myocardial infarction, unstable angina pectoris, or congestive heart failure of class II or greater according to the New York Heart Association criteria, severe arrhythmia requiring medication
- Pregnant or breastfeeding women
- Participation in other therapeutic clinical trials during the course of the patient's illness in which the treatment cannot be specified or information about the treatment cannot be collected
Interventions
Routine surgical operations for patients with hepatocellular carcinoma, such as surgical resection, ablation，TACE，HAIC
Use of anti-tumor drugs, e.g., immunologic, targeted, and chemotherapy drugs
Locations(38)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06777485